CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Veru Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Veru Inc
2916 N. MIAMI AVENUE, SUITE 1000
Phone: (312) 595-9123p:312 595-9123 MIAMI, FL  33127  United States Ticker: VERUVERU
Business Summary
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20249/30/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Mitchell S.Steiner 63 3/1/2018 10/31/2016
Vice Chairman of the Board, Chief Corporate Officer HarryFisch 65 3/1/2018 10/31/2016
Chief Financial Officer, Chief Administrative Officer MicheleGreco 65 3/1/2018 1/1/2013
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
THE FEMALE HEALTH COMPANY (UK) PLC 3 WESTERN AVENUE BUSINESS PARK MANSFIELD ROAD UK

Business Names
Business Name
Aspen Park Pharmaceuticals, Inc.
Badger Acquisition Sub, Inc.
FHCO
7 additional Business Names available in full report.

General Information
Number of Employees: 210 (As of 10/31/2024)
Outstanding Shares: 146,383,920 (As of 9/30/2024)
Shareholders: 148
Stock Exchange: NASD
Federal Tax Id: 391144397
Fax Number: (312) 595-9122
Email Address: info@femalehealth.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 30, 2025